EZH2 is overexpressed or dysfunctional in numerous types of cancer, and EZH2 inhibitors exert their anti-tumor effects by blocking its methyltransferase activity, thereby reactivating silenced genes [176]. The gene discussed is EZH2; the disease is neoplasm.